



# midazolam 2mg/mL oral solution in single-dose container (Ozalin®)

Primex Pharmaceuticals

10 September 2021

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**midazolam oral solution (Ozalin®)** is accepted for use within NHSScotland.

**Indication under review:** in children from 6 months to 17 years old, for moderate sedation before a therapeutic or diagnostic procedure or as premedication before anaesthesia.

Ozalin® 2mg/mL oral solution is supplied in single-use glass ampoules and the dose must be measured using the oral applicator, which is graduated in kg of body weight, and the filter straw provided.

The availability of midazolam oral solution (Ozalin®) provides a licensed alternative to an unlicensed preparation.

## Advice context:

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

**Chairman  
Scottish Medicines Consortium**